Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers.
Siripongboonsitti T, Ungtrakul T, Watanapokasin N, Timsri P, Wongpakdee K, Wattanasin P, Pavitrapok C, Khunvichai A, Jamnongtanachot P, Mueannoom W, Kitpoka T, Arjharn W, Mahanonda N. Siripongboonsitti T, et al. Among authors: mahanonda n. Clin Pharmacol Drug Dev. 2023 Jan;12(1):14-20. doi: 10.1002/cpdd.1149. Epub 2022 Jul 25. Clin Pharmacol Drug Dev. 2023. PMID: 35877195 Clinical Trial.
The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.
Siripongboonsitti T, Tawinprai K, Cheirsilpa K, Ungtrakul T, Krisorakun W, Chotipanich C, Wimolsiri N, Noitun P, Srirattana N, Mahanonda N. Siripongboonsitti T, et al. Among authors: mahanonda n. Medicina (Kaunas). 2023 Jun 6;59(6):1098. doi: 10.3390/medicina59061098. Medicina (Kaunas). 2023. PMID: 37374302 Free PMC article.
Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial).
Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C. Siripongboonsitti T, et al. Among authors: mahanonda n. Phytomedicine. 2023 Oct;119:155018. doi: 10.1016/j.phymed.2023.155018. Epub 2023 Aug 12. Phytomedicine. 2023. PMID: 37625206 Free article. Clinical Trial.
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
Siripongboonsitti T, Ungtrakul T, Tawinprai K, Nimmol T, Buttakosa M, Sornsamdang G, Jarrusrojwuttikul T, Silapant P, Mahanonda N. Siripongboonsitti T, et al. Among authors: mahanonda n. Int J Infect Dis. 2023 Sep;134:211-219. doi: 10.1016/j.ijid.2023.06.018. Epub 2023 Jun 30. Int J Infect Dis. 2023. PMID: 37393041 Free article. Clinical Trial.
SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand.
Ungtrakul T, Sornsamdang G, Soonklang K, Saeloo S, Wittayasak K, Suptawiwat O, Pulmanausahakul R, Phattraprayoon N, Auewarakul C, Mahanonda N. Ungtrakul T, et al. Among authors: mahanonda n. Public Health Pract (Oxf). 2022 Dec;4:100341. doi: 10.1016/j.puhip.2022.100341. Epub 2022 Nov 6. Public Health Pract (Oxf). 2022. PMID: 36373034 Free PMC article.
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab).
Siripongboonsitti T, Nontawong N, Tawinprai K, Suptawiwat O, Soonklang K, Poovorawan Y, Mahanonda N. Siripongboonsitti T, et al. Among authors: mahanonda n. Microbiol Spectr. 2023 Dec 12;11(6):e0325723. doi: 10.1128/spectrum.03257-23. Epub 2023 Nov 17. Microbiol Spectr. 2023. PMID: 37975699 Free PMC article. Clinical Trial.
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10-17 Years in Thailand.
Thonginnetra S, Tawinprai K, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N, Ruangkijpaisal N, Banomyong N, Phattraprayoon N, Rangkakulnuwat P, Vanichsetakul P, Ungtrakul T, Wittayasak K, Thonwirak N, Soonklang K, Mahanonda N. Thonginnetra S, et al. Among authors: mahanonda n. Vaccines (Basel). 2022 Oct 21;10(10):1765. doi: 10.3390/vaccines10101765. Vaccines (Basel). 2022. PMID: 36298630 Free PMC article.
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study.
Nontawong N, Siripongboonsitti T, Tawinprai K, Boonpratoom M, Krailassiri N, Boonkhum C, Soonklang K, Poovorawan Y, Mahanonda N. Nontawong N, et al. Among authors: mahanonda n. Ann Clin Microbiol Antimicrob. 2022 Nov 19;21(1):51. doi: 10.1186/s12941-022-00542-2. Ann Clin Microbiol Antimicrob. 2022. PMID: 36403020 Free PMC article.
84 results